Skip to search formSkip to main contentSkip to account menu

idelalisib

Known as: 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H- quinazolin-4-one, 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one, 5-fluoro-3-phenyl-2-[(1S)-1-(3H-purin-6-ylamino)propyl]quinazolin-4(3H)-one 
An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K… 
National Institutes of Health

Related topics

Related topics

10 relations

Broader (4)

Antineoplastic AgentsEnzyme InhibitorsPurinesQuinazolinones

Narrower (2)

CAL 101Zydelig
GS-1101Kinase Inhibitors [MoA]NCIt Antineoplastic Agent Terminologyidelalisib 150 MG Oral Tablet [Zydelig]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Balancing early access with uncertainties in evidence for drugs authorized by prospective case series – systematic review of reimbursement decisions
To review clinical and cost‐effectiveness evidence underlying reimbursement decisions relating to drugs whose authorization… 
2017
2017
SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
2015
2015
Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials.
e18030 Background: Idelalisib (Zydelig), a first-in-class, selective, oral inhibitor of PI3Kδ, is approved in the US and EU for… 
2015
2015
Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo…
Introduction: Idelalisib (IDELA) is a 1st-in-class targeted PI3k delta inhibitor approved in combination with rituximab for the… 
Highly Cited
2013
Highly Cited
2013
A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic…
7005 Background: PI3K-delta is critical for activation, proliferation and survival of B cells and plays a role in homing and… 
2013
2013
Design and synthesis of some new quinazolin-4-(3H)-ones as anticonvulsant and antidepressant agents
A series of 3-[(4-substituted-benzylidene)-amino]-2-phenyl-3H-quinazolin-4-ones (5a–k) were synthesized by reacting 3-amino-2… 
2013
2013
Pharmacokinetics, Metabolism and Excretion Of Idelalisib
Background PI3K-delta is critical for activation, proliferation and survival of B cells and plays a role in homing and retention… 
2007
2007
Synthesis and pharmacological investigation of novel 3‐(3‐methylphenyl)‐2‐substituted amino‐3H‐quinazolin‐4‐ones as analgesic and anti‐inflammatory agents
A variety of novel 3‐(3‐methylphenyl)‐2‐substituted amino‐3H‐quinazolin‐4‐ones were synthesized by reacting the amino group of 2… 
2006
2006
Synthesis and pharmacological investigation of novel 1‐substituted‐4‐(4‐substituted phenyl)‐4H‐[1,2,4]triazolo[4,3‐a]quinazolin‐5‐ones as a new class of H1‐antihistamine agents
A series of novel 1‐substituted‐4‐(4‐substituted phenyl)‐4H‐[1,2,4]triazolo[4,3‐a]quinazolin‐5‐ones was synthesized by the… 
2005
2005
Force field design and molecular dynamics simulations of the carbapenem- and cephamycin-resistant dinuclear zinc metallo-beta-lactamase from Bacteroides fragilis and its complex with a biphenyl…
On the basis of molecular dynamics simulations, we investigate the dynamic properties of the carbapenem- and cephamycin-resistant… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)